An initiative to transform the generic pharmaceuticals business model and build an ecosystem covering the active pharmaceutical ingredients business and the Indian plant through the capital and business alliance with 日医工. This also includes the transfer of shares in Elmed Eisai and the partial termination of the collaboration agreement.